XML 49 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements on a Recurring Basis
The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis (in thousands):
Fair Value as of March 31, 2021Fair Value Measurements Using Inputs Considered as:
Level 1Level 2Level 3
Assets:
Derivative assets - designated as cash flow hedges (foreign currency exchange rate “FX”)$1,379 $— $1,379 $— 
Derivative assets - freestanding instruments (FX)863 — 863 — 
Derivative assets - capped call derivatives84,852 — — 84,852 
Convertible notes receivable2,758 — — 2,758 
$89,852 $— $2,242 $87,610 
Liabilities:
Derivative liabilities - designated as cash flow hedges (FX)$724 $— $724 $— 
Derivative liabilities - freestanding instruments (interest rate swaps)36 — 36 — 
Derivative liabilities - freestanding instruments (FX) 705 — 705 — 
Derivative liabilities - embedded exchange feature148,091 — — 148,091 
Derivative liabilities - other1,123 — — 1,123 
Contingent consideration arrangements99,271 — — 99,271 
$249,950 $— $1,465 $248,485 

Fair Value as of December 31, 2020Fair Value Measurements Using Inputs Considered as:
Level 1Level 2Level 3
Assets:
Derivative assets - designated as cash flow hedges (FX)$2,893 $— $2,893 $— 
Derivative assets - freestanding instruments (FX)55 — 55 — 
Derivative assets - capped call derivatives72,302 — — 72,302 
Convertible notes receivable2,775 — — 2,775 
$78,025 $— $2,948 $75,077 
Liabilities:
Derivative liabilities - designated as cash flow hedges (FX)$14 $— $14 $— 
Derivative liabilities - freestanding instruments (interest rate swaps)74 — 74 — 
Derivative liabilities - freestanding instruments (FX) 4,073 — 4,073 — 
Derivative liabilities - embedded exchange feature121,756 — — 121,756 
Derivative liabilities - other4,290 — — 4,290 
Contingent consideration arrangements103,818 — — 103,818 
$234,025 $— $4,161 $229,864 
Reconciliation of Beginning and Ending Balances of Contingent Consideration
The following table provides a reconciliation of the beginning and ending balances of our recurring fair value measurements, using significant unobservable inputs (Level 3) (in thousands):
Capped Call Derivative AssetConvertible Notes ReceivableEmbedded Exchange Feature Derivative LiabilityOther Derivative LiabilitiesContingent Consideration Liability Arrangements
As of December 31, 2020$72,302 $2,775 $121,756 $4,290 $103,818 
Payments (1)
— — — — (5,000)
Changes in fair value12,550 (17)26,335 (3,167)453 
Total at March 31, 202184,852 2,758 148,091 1,123 99,271 
Less current portion at March 31, 2021— 2,495 — 931 9,424 
Long-term portion at March 31, 2021$84,852 $263 $148,091 $192 $89,847 
(1)During the three months ended March 31, 2021, we paid $5.0 million under the contingent consideration arrangement for the acquisition of Miami Instruments, LLC (“Miami Instruments”).
Schedule of Business Acquisitions by Acquisition, Contingent Consideration
The following table provides the fair value of our Level 3 contingent consideration arrangements by acquisition (in thousands):
March 31, 2021December 31, 2020
ImThera Medical, Inc. (“ImThera”)$89,426 $89,436 
CardiacAssist, Inc., doing business as TandemLife (“TandemLife”)8,942 8,809 
Miami Instruments903 5,573 
$99,271 $103,818 
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation Both arrangements are Level 3 fair value measurements and include the following significant unobservable inputs as of March 31, 2021:
ImThera AcquisitionValuation TechniqueUnobservable InputInputs
Regulatory milestone-based paymentDiscounted cash flowDiscount rate6.7%
Probability of payment85%
Projected payment year2024
Sales-based earnoutMonte Carlo simulationRisk-adjusted discount rate12.0%-12.7%
Credit risk discount rate7.0% -7.8%
Revenue volatility32.5%
Probability of payment85%
Projected years of earnout2025-2028
The TandemLife business combination involved a contingent consideration arrangement composed of potential cash payments upon the achievement of certain regulatory milestones. The arrangement is a Level 3 fair value measurement and includes the following significant unobservable inputs as of March 31, 2021:
TandemLife AcquisitionValuation TechniqueUnobservable InputInputs
Regulatory milestone-based paymentDiscounted cash flowDiscount rate4.9%
Probability of payment70%
Projected payment year2021